Computed tomography density changes of bone metastases after concomitant denosumab

Area of Science:

• Oncology
• Radiology
• Bone Metabolism

Background:

• Bone metastases are a common complication in cancer patients.
• Denosumab is a monoclonal antibody used to treat bone metastases.
• Evaluating bone density changes is crucial for assessing treatment efficacy.

Purpose of the Study:

• To assess bone density changes in normal trabecular bone and bone metastases after denosumab treatment.
• To evaluate the long-term effects of denosumab on bone density in cancer patients.

Main Methods:

• Retrospective evaluation of 31 adult patients with solid tumors and bone metastases.
• Patients received denosumab (120 mg subcutaneously every 28 days) for at least 6 months.
• Bone density was measured using CT and a region of interest (ROI)-based approach in bone metastases and normal lumbar vertebrae.

Main Results:

• Progressive increase in CT bone density in normal trabecular bone at 6 months (18% ± 5%) and 12 months (23% ± 7%).
• Significant increase in CT bone density in bone metastases after 6 months (57% ± 15%) and 12 months (1.06 ± 0.25 times higher).
• The effect of denosumab on bone density was more pronounced in osteolytic metastases.

Conclusions:

• Long-term denosumab treatment progressively increases bone density in oncologic patients.
• Bone density increases are observed in both normal trabecular bone and bone metastases.
• Denosumab is effective in improving bone density in patients with bone metastases, particularly osteolytic lesions.